The clinical application for ASKC852 tablets of Aosaike was approved by CDE...

On April 23, Osaikang declared a new drug clinical application for the first class of new drug ASKC852 tablets, which was undertaken by CDE, which is a small molecule immunomodulatory drug.

Figure 1: The new drug that Osaikang has declared for clinical use this time

Source: CDE official website

According to data, ASKC852 is a new class 1 drug jointly developed by Aosaekang and Shanghai WuXi AppTec.

In the earlier pharmacodynamic experiment, ASKC852 single agent can have a significant inhibitory effect on tumors, and when combined with PD-L1 monoclonal antibody, it can also produce excellent synergistic effects, making PD-L1 monoclonal antibody anti-tumor effect Significantly improved.

Figure 2: New drugs declared and under review by Osaikang this year

Source: Meinenet MED2.

It is reported that dexlansoprazole is a proton pump inhibitor and is the R-isomer of lansoprazole.

Table 1: Part of the latest developments of Aosaiken's Class 1 and Class 2 new drugs

Source: Meinenet MED2.

Source: Minet database, CDE official website

The review data statistics are as of April 26, if there are any errors or omissions, please correct me.